1. Home
  2. GBIO vs DOUG Comparison

GBIO vs DOUG Comparison

Compare GBIO & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.41

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$2.45

Market Cap

219.1M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBIO
DOUG
Founded
2016
1911
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
36.3M
219.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GBIO
DOUG
Price
$5.41
$2.45
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$8.88
N/A
AVG Volume (30 Days)
61.5K
300.5K
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,270,000.00
$1,030,928,000.00
Revenue This Year
N/A
$17.61
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.67
52 Week Low
$3.00
$1.48
52 Week High
$12.50
$3.20

Technical Indicators

Market Signals
Indicator
GBIO
DOUG
Relative Strength Index (RSI) 55.34 42.70
Support Level $5.20 $2.66
Resistance Level $5.54 $2.90
Average True Range (ATR) 0.24 0.11
MACD 0.04 -0.02
Stochastic Oscillator 79.66 4.35

Price Performance

Historical Comparison
GBIO
DOUG

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.

Share on Social Networks: